(19)
(11) EP 3 630 754 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
31.08.2022 Bulletin 2022/35

(45) Mention of the grant of the patent:
27.07.2022 Bulletin 2022/30

(21) Application number: 18728875.8

(22) Date of filing: 01.06.2018
(51) International Patent Classification (IPC): 
C07D 417/12(2006.01)
A61P 35/00(2006.01)
 C07D 417/14(2006.01)
A61K 31/427(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 417/12; C07D 417/14
(86) International application number:
PCT/EP2018/064399
(87) International publication number:
WO 2018/220149 (06.12.2018 Gazette 2018/49)

(54)

ISOINDOLINE-ACETYLENE COMPOUNDS FOR THE TREATMENT OF CANCER

ISOINDOLINE-ACETYLEN VERBINDUNGEN ZUR BEHANDLUNG VON KREBS

COMPOSES D'ISOINDOLINE-ACETYLENE POUR LE TRAITEMENT DU CANCER

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Validation States:
MA

(30) Priority: 02.06.2017 EP 17174334
02.06.2017 US 201762514244 P
10.08.2017 US 201762543438 P

(43) Date of publication of application:
08.04.2020 Bulletin 2020/15

(73) Proprietor: F. Hoffmann-La Roche AG
4070 Basel (CH)

(72) Inventors:
  • JAESCHKE, Georg
    4070 Basel (CH)
  • RICCI, Antonio
    4070 Basel (CH)
  • RUEHER, Daniel
    4070 Basel (CH)
  • STEINER, Sandra
    4070 Basel (CH)
  • DUPLESSIS, Martin
    Watertown MA 02472 (US)
  • NAGEL, Yvonne Alice
    4070 Basel (CH)
  • KUHN, Bernd
    4070 Basel (CH)

(74) Representative: Pomeranc, Didier 
F. Hoffmann-La Roche AG Patent Department Grenzacherstrasse 124
4070 Basel
4070 Basel (CH)


(56) References cited: : 
WO-A1-2009/158369
 WO-A1-2016/183534
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).